報告摘要

The global Pneumococcal Conjugate Vaccine (PCV) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032. North America: the Pneumococcal Conjugate Vaccine (PCV) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pneumococcal Conjugate Vaccine (PCV) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Pneumococcal Conjugate Vaccine (PCV) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pneumococcal Conjugate Vaccine (PCV) include Sanofi, Merck, Pfizer, GSK, Zhifei Biologic, Walvax Biotechnology, Serum Institute of India and Royal (Wuxi) Bio-Pharmaceutical, among others; in 2025, the top three vendors together accounted for approximately % of global revenue. Report Scope This report quantifies the global Pneumococcal Conjugate Vaccine (PCV) market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032. It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pneumococcal Conjugate Vaccine (PCV). Key Companies & Market Share Insights This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking. Pneumococcal Conjugate Vaccine (PCV) Market by Company Sanofi Merck Pfizer GSK Zhifei Biologic Walvax Biotechnology Serum Institute of India Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Segment by Type 10-valent Vaccine 13-valent Vaccine 23-valent Vaccine 7-valent Vaccine Pneumococcal Conjugate Vaccine (PCV) Segment by Application Child Adult Pneumococcal Conjugate Vaccine (PCV) Segment by Region North America United States Canada Europe Germany France U.K. Italy Spain Russia Netherlands Nordic Countries Asia-Pacific China Japan South Korea India Australia China Taiwan Southeast Asia South America Mexico Brazil Argentina Middle East & Africa Saudi Arabia Israel United Arab Emirates Turkey Iran Egypt Key Drivers & Barriers High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects. Reasons to Buy This Report 1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Conjugate Vaccine (PCV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market. 2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Conjugate Vaccine (PCV) and provides them with information on key market drivers, restraints, challenges, and opportunities. 3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition. 4. This report stays updated with novel technology integration, features, and the latest developments in the market 5. This report helps stakeholders to gain insights into which regions to target globally 6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Conjugate Vaccine (PCV). 7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution. Chapter Outline Chapter 1: Research objectives, research methods, data sources, data cross-validation; Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term. Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry. Chapter 6: Detailed analysis of Pneumococcal Conjugate Vaccine (PCV) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc. Chapter 13: The main points and conclusions of the report.

目錄 Table of Contents

1 Preface 1.1 Scope of Report 1.2 Reasons for Doing This Study 1.3 Research Methodology 1.4 Research Process 1.5 Data Source 1.5.1 Secondary Sources 1.5.2 Primary Sources 2 Market Overview 2.1 Product Definition 2.2 Pneumococcal Conjugate Vaccine (PCV) by Type 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) 2.2.2 10-valent Vaccine 2.2.3 13-valent Vaccine 2.2.4 23-valent Vaccine 2.2.5 7-valent Vaccine 2.3 Pneumococcal Conjugate Vaccine (PCV) by Application 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) 2.3.2 Child 2.3.3 Adult 2.4 Assumptions and Limitations 3 Pneumococcal Conjugate Vaccine (PCV) Breakdown Data by Type 3.1 Global Pneumococcal Conjugate Vaccine (PCV) Historic Market Size by Type (2021-2026) 3.2 Global Pneumococcal Conjugate Vaccine (PCV) Forecasted Market Size by Type (2027-2032) 4 Pneumococcal Conjugate Vaccine (PCV) Breakdown Data by Application 4.1 Global Pneumococcal Conjugate Vaccine (PCV) Historic Market Size by Application (2021-2026) 4.2 Global Pneumococcal Conjugate Vaccine (PCV) Forecasted Market Size by Application (2027-2032) 5 Global Growth Trends 5.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Perspective (2021-2032) 5.2 Global Pneumococcal Conjugate Vaccine (PCV) Growth Trends by Region 5.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region: 2021 VS 2025 VS 2032 5.2.2 Pneumococcal Conjugate Vaccine (PCV) Historic Market Size by Region (2021-2026) 5.2.3 Pneumococcal Conjugate Vaccine (PCV) Forecasted Market Size by Region (2027-2032) 5.3 Pneumococcal Conjugate Vaccine (PCV) Market Dynamics 5.3.1 Pneumococcal Conjugate Vaccine (PCV) Industry Trends 5.3.2 Pneumococcal Conjugate Vaccine (PCV) Market Drivers 5.3.3 Pneumococcal Conjugate Vaccine (PCV) Market Challenges 5.3.4 Pneumococcal Conjugate Vaccine (PCV) Market Restraints 6 Market Competitive Landscape by Players 6.1 Global Top Pneumococcal Conjugate Vaccine (PCV) Players by Revenue 6.1.1 Global Top Pneumococcal Conjugate Vaccine (PCV) Players by Revenue (2021-2026) 6.1.2 Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Players (2021-2026) 6.2 Global Pneumococcal Conjugate Vaccine (PCV) Industry Players Ranking, 2023 VS 2024 VS 2025 6.3 Global Key Players of Pneumococcal Conjugate Vaccine (PCV) Head Office and Area Served 6.4 Global Pneumococcal Conjugate Vaccine (PCV) Players, Product Type & Application 6.5 Global Pneumococcal Conjugate Vaccine (PCV) Manufacturers Established Date 6.6 Global Pneumococcal Conjugate Vaccine (PCV) Market CR5 and HHI 6.7 Global Players Mergers & Acquisition 7 North America 7.1 North America Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) 7.2 North America Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032 7.3 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) 7.4 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) 7.5 United States 7.5 United States 7.6 Canada 7.7 Mexico 8 Europe 8.1 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) 8.2 Europe Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032 8.3 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) 8.4 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) 8.5 Germany 8.6 France 8.7 U.K. 8.8 Italy 8.9 Spain 8.10 Russia 8.11 Netherlands 8.12 Nordic Countries 9 Asia-Pacific 9.1 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) 9.2 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032 9.3 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) 9.4 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) 9.5 China 9.6 Japan 9.7 South Korea 9.8 India 9.9 Australia 9.10 China Taiwan 9.11 Southeast Asia 10 South America 10.1 South America Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) 10.2 South America Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032 10.3 South America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) 10.4 South America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) 10.5 Brazil 10.6 Argentina 10.7 Chile 10.8 Colombia 10.9 Peru 11 Middle East & Africa 11.1 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) 11.2 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032 11.3 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) 11.4 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) 11.5 Saudi Arabia 11.6 Israel 11.7 United Arab Emirates 11.8 Turkey 11.9 Iran 11.10 Egypt 12 Players Profiled 12.1 Sanofi 12.1.1 Sanofi Company Information 12.1.2 Sanofi Business Overview 12.1.3 Sanofi Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) 12.1.4 Sanofi Pneumococcal Conjugate Vaccine (PCV) Product Portfolio 12.1.5 Sanofi Recent Developments 12.2 Merck 12.2.1 Merck Company Information 12.2.2 Merck Business Overview 12.2.3 Merck Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) 12.2.4 Merck Pneumococcal Conjugate Vaccine (PCV) Product Portfolio 12.2.5 Merck Recent Developments 12.3 Pfizer 12.3.1 Pfizer Company Information 12.3.2 Pfizer Business Overview 12.3.3 Pfizer Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) 12.3.4 Pfizer Pneumococcal Conjugate Vaccine (PCV) Product Portfolio 12.3.5 Pfizer Recent Developments 12.4 GSK 12.4.1 GSK Company Information 12.4.2 GSK Business Overview 12.4.3 GSK Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) 12.4.4 GSK Pneumococcal Conjugate Vaccine (PCV) Product Portfolio 12.4.5 GSK Recent Developments 12.5 Zhifei Biologic 12.5.1 Zhifei Biologic Company Information 12.5.2 Zhifei Biologic Business Overview 12.5.3 Zhifei Biologic Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) 12.5.4 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product Portfolio 12.5.5 Zhifei Biologic Recent Developments 12.6 Walvax Biotechnology 12.6.1 Walvax Biotechnology Company Information 12.6.2 Walvax Biotechnology Business Overview 12.6.3 Walvax Biotechnology Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) 12.6.4 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product Portfolio 12.6.5 Walvax Biotechnology Recent Developments 12.7 Serum Institute of India 12.7.1 Serum Institute of India Company Information 12.7.2 Serum Institute of India Business Overview 12.7.3 Serum Institute of India Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) 12.7.4 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product Portfolio 12.7.5 Serum Institute of India Recent Developments 12.8 Royal (Wuxi) Bio-Pharmaceutical 12.8.1 Royal (Wuxi) Bio-Pharmaceutical Company Information 12.8.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview 12.8.3 Royal (Wuxi) Bio-Pharmaceutical Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) 12.8.4 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product Portfolio 12.8.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments 13 Report Conclusion 14 Disclaimer

圖表清單 List of Tables & Figures

List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Type (2021-2026) Table 7. Global Pneumococcal Conjugate Vaccine (PCV) Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Type (2027-2032) Table 9. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Application (2021-2026) Table 11. Global Pneumococcal Conjugate Vaccine (PCV) Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Application (2027-2032) Table 13. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region (2021-2026) Table 16. Global Pneumococcal Conjugate Vaccine (PCV) Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region (2027-2032) Table 18. Pneumococcal Conjugate Vaccine (PCV) Industry Trends Table 19. Pneumococcal Conjugate Vaccine (PCV) Industry Drivers Table 20. Pneumococcal Conjugate Vaccine (PCV) Industry Opportunities and Challenges Table 21. Pneumococcal Conjugate Vaccine (PCV) Market Restraints Table 22. Global Top Pneumococcal Conjugate Vaccine (PCV) Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Players (2021-2026) Table 24. Global Pneumococcal Conjugate Vaccine (PCV) Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Pneumococcal Conjugate Vaccine (PCV), Headquarters and Area Served Table 26. Global Pneumococcal Conjugate Vaccine (PCV) Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Pneumococcal Conjugate Vaccine (PCV) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) & (US$ Million) Table 45. Sanofi Company Information Table 46. Sanofi Business Overview Table 47. Sanofi Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) & (US$ Million) Table 48. Sanofi Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 49. Sanofi Recent Developments Table 50. Merck Company Information Table 51. Merck Business Overview Table 52. Merck Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) & (US$ Million) Table 53. Merck Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 54. Merck Recent Developments Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) & (US$ Million) Table 58. Pfizer Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 59. Pfizer Recent Developments Table 60. GSK Company Information Table 61. GSK Business Overview Table 62. GSK Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) & (US$ Million) Table 63. GSK Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 64. GSK Recent Developments Table 65. Zhifei Biologic Company Information Table 66. Zhifei Biologic Business Overview Table 67. Zhifei Biologic Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) & (US$ Million) Table 68. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 69. Zhifei Biologic Recent Developments Table 70. Walvax Biotechnology Company Information Table 71. Walvax Biotechnology Business Overview Table 72. Walvax Biotechnology Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) & (US$ Million) Table 73. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 74. Walvax Biotechnology Recent Developments Table 75. Serum Institute of India Company Information Table 76. Serum Institute of India Business Overview Table 77. Serum Institute of India Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) & (US$ Million) Table 78. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 79. Serum Institute of India Recent Developments Table 80. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 81. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 82. Royal (Wuxi) Bio-Pharmaceutical Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) & (US$ Million) Table 83. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 84. Royal (Wuxi) Bio-Pharmaceutical Recent Developments Table 85. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Pneumococcal Conjugate Vaccine (PCV) Product Image Figure 5. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Type: 2025 VS 2032 Figure 7. 10-valent Vaccine Product Figure 8. 13-valent Vaccine Product Figure 9. 23-valent Vaccine Product Figure 10. 7-valent Vaccine Product Figure 11. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Application: 2025 VS 2032 Figure 13. Child Product Figure 14. Adult Product Figure 15. Global Pneumococcal Conjugate Vaccine (PCV) Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 16. Global Pneumococcal Conjugate Vaccine (PCV) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region: 2025 VS 2032 Figure 18. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Players in 2025 Figure 19. Global Pneumococcal Conjugate Vaccine (PCV) Manufacturers Established Date Figure 20. Global Top 5 and 10 Pneumococcal Conjugate Vaccine (PCV) Players Market Share by Revenue in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. North America Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 24. United States Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Canada Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Mexico Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 27. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. Europe Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 29. Germany Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. France Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. U.K. Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Italy Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Spain Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Russia Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Netherlands Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Nordic Countries Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 39. China Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Japan Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. South Korea Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. India Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 44. Australia Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. China Taiwan Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. South America Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 49. Brazil Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Argentina Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Chile Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Colombia Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Peru Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Sanofi Revenue Growth Rate in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) Figure 55. Merck Revenue Growth Rate in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) Figure 56. Pfizer Revenue Growth Rate in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) Figure 57. GSK Revenue Growth Rate in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) Figure 58. Zhifei Biologic Revenue Growth Rate in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) Figure 59. Walvax Biotechnology Revenue Growth Rate in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) Figure 60. Serum Institute of India Revenue Growth Rate in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026) Figure 61. Royal (Wuxi) Bio-Pharmaceutical Revenue Growth Rate in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026)

Single User	$2,950 USD
Multi User	$4,430 USD
Enterprise	$5,900 USD

Pneumococcal Conjugate Vaccine (PCV) Industry Research Report 2026

授權報價

報告摘要

提及公司